Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Analysts
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in […]
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in […]
